TEL AVIV, Israel--(BUSINESS WIRE)--InspireMD, Ltd. today announced that its MGuardTM Coronary Stent has received CE Mark approval to treat patients with coronary artery diseases. The CE Mark allows MGuard™ Coronary to gain access to markets in the European Union (“EU”). In addition, the approval clears the way to market the MGuardTM Coronary in other countries that recognize the CE Mark in Europe, Latin America, Asia and Africa. “This is a major achievement for InspireMD,” said Ofir Paz, InspireMD Chief Executive Officer and Chairman of the Board. “MGuard™ Coronary stent receives the ‘green light’ to compete in a market worth more than $3 billion annually. Designed to enhance the safety of stenting procedures, we are confident that MGuard™ Coronary provides advantages over other available coronary stents and is well positioned to capture a significant share of this large and growing market.”
